- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00161746
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
May 20, 2015 updated by: Pfizer
Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in terms of safety between the two products.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kapfenberg, Austria, 8605
- Wiener Strasse 50/2
-
Leoben, Austria, 8700
- Erzherzog Johann Strasse 9
-
Liezen, Austria, 8940
- Fronleichnamsweg 10
-
Linz, Austria, 4040
- Hauptstrasse 61
-
Mürzzuschlag, Austria, 8680
- Brauhausgasse 1
-
Voitsberg, Austria, 8570
- Conrad-von-Hötzendorf Strasse
-
Wels, Austria, 4600
- Grieskirchner Strasse 17
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 3 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female children aged between 6 and 47 months
- No history of any previous TBE vaccination
- Clinically healthy
- Informed consent provided by the parents
Exclusion Criteria:
- History of allergic reactions, in particular allergic reactions to one of the components of the vaccine
- Suffering from a disease that cannot be effectively treated or stabilised
- Suffering from a disease or undergoing a form of treatment which can be expected to influence immunological functions
- Suffering from a chronic, degenerative and/or inflammatory disease of the central nervous system
- HIV-positivity (no special HIV test required for the purpose of the study)
- Suffering from a febrile disease
- History of vaccination against yellow fever and/or Japanese encephalitis
- Participation in another clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 1998
Study Completion
June 1, 1999
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 13, 2005
Study Record Updates
Last Update Posted (Estimate)
May 21, 2015
Last Update Submitted That Met QC Criteria
May 20, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Tick-Borne Diseases
- Encephalitis
- Encephalitis, Tick-Borne
Other Study ID Numbers
- 146A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Encephalitis, Tick-borne
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)TerminatedTick-Borne Disease | Encephalitis, Tick-Borne | Tick-Borne Encephalitis | Glycoprotein E, Flavivirus | NSI Protein, FlavivirusUnited States
-
Medical University of ViennaAustrian Science Fund (FWF)CompletedTick Borne EncephalitisAustria
-
PfizerCompletedTick-borne Encephalitis (TBE)Poland
-
Sykehuset TelemarkNorwegian Institute of Public Health; Oslo University Hospital; Sorlandet Hospital... and other collaboratorsRecruiting
-
PfizerCompleted
-
GlaxoSmithKlineNovartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthCompletedTick-Borne EncephalitisUnited States
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaRecruiting
-
University of SurreyCompletedTick-Borne EncephalitisUnited Kingdom
Clinical Trials on Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
-
PfizerCompletedEncephalitis, Tick-borneBelgium
-
PfizerCompletedEncephalitis, Tick-borneAustria, Germany
-
PfizerCompletedEncephalitis, Tick-bornePoland
-
PfizerCompletedEncephalitis, Tick-bornePoland
-
PfizerCompletedEncephalitis, Tick-BorneGermany, Austria, Poland
-
PfizerCompletedEncephalitis, Tick-borneGermany
-
PfizerCompletedEncephalitis, Tick-BornePoland
-
PfizerCompletedEncephalitis, Tick-BorneAustria, Czechia
-
NovartisNovartis VaccinesCompletedEncephalitis, Tick-BorneGermany
-
PfizerCompletedTick-borne EncephalitisAustria, Germany